AbbVie to focus on smaller deals after buying spree | Reuters

Dec 7, 2023 · AbbVie to focus on smaller deals after buying spree. By Reuters. December 7, 2023 10:04 PM UTC Updated ago A woman holds a test tube in front of displayed Abbvie logo in …

$10
OFF

ImmunoGen Inc | Reuters

2 weeks from now

Jan 8, 2024 · AbbVie to focus on smaller deals after buying spree. ... AbbVie will buy ImmunoGen for $10.1 billion in cash, it said on Thursday, the latest major drugmaker to acquire a maker of …

reuters.com

$2
OFF

Abbvie Plans To Lift $2 Billion Cap On Deals - WSJ | Reuters

2 weeks from now

Feb 6, 2023 · Abbvie will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the …

reuters.com

FAQs about AbbVie to focus on smaller deals after buying spree | Reuters Coupon?

Why is AbbVie focusing on smaller deals?

U.S. drugmaker AbbVie said on Thursday it intends to focus on smaller deals to support its growth through the next decade, after it struck two multibillion dollar deals in the past week to acquire Cerevel Therapeutics and ImmunoGen . ...

Will AbbVie return to 'robust growth' in 2025?

"I would not anticipate similar sized transactions for the foreseeable future," said AbbVie's Chief Operating Officer Robert Michael on a conference call, referring to the company's $8.7 billion buyout of Cerevel Therapeutics (CERE.O) announced on Wednesday. AbbVie said it expects to return to "robust growth" in 2025, after its recent buying spree. ...

Does AbbVie have a $2 billion deal with Allergan?

REUTERS/Brian Snyder/ Purchase Licensing Rights Feb 6 (Reuters) - Abbvie (ABBV.N) will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the company's chief executive officer told the Wall Street Journal. ...

Will cerevel & AbbVie get FTC approval?

Some Wall Street analysts raised concerns that Cerevel's treatments under development might overlap with AbbVie's products, presenting a potential risk for the deal to get approval from the U.S. Federal Trade Commission. Gonzalez said AbbVie has "confidence" the deal will get through the FTC. ...

Will AbbVie's Vraylar deal get through the FTC?

Gonzalez said AbbVie has "confidence" the deal will get through the FTC. AbbVie's Vraylar is approved for schizophrenia, bipolar disorder and major depressive disorder. The U.S. drugmaker also has its Parkinson's disease treatment Duodopa in the market and another candidate ABBV-951 in development. ...

Will AbbVie replace Humira with rinvoqn?

Abbvie is hoping to replace the loss of revenue from Humira through its newer immunology drugs Skyrizi and Rinvoqn, and has forecast sales of over $21 billion from the two products in 2027. Our Standards: The Thomson Reuters Trust Principles. ...